A new paper published in JNCI: Journal of the National Cancer Institute indicates that receiving assisted reproductive technology does not increase the risk women have for developing ovarian cancer.
Researchers at the UCLA Jonsson Comprehensive Cancer Center found patients with a particular type of human leukocyte antigen (HLA), a protein scaffold involved in presenting pieces of proteins described as peptides to the immune system, were particularly likely to benefit from immunotherapy.
Researchers at NYU Grossman School of Medicine and Perlmutter Cancer Center trained a computer to tell which skin cancer patients may benefit from drugs that keep tumors from shutting down the immune system's attack on them.
Phase III trial data shows that a developmental drug, plinabulin, could help keep cancer patients on needed chemotherapy treatments.
Nerlynx (neratinib) demonstrates a 5.1% invasive disease-free survival benefit versus placebo in the phase III ExteNET trial evaluating Nerlynx in HER2-positive, hormone receptor-positive early stage breast cancer.
In a phase III trial, Keytruda (pembrolizumab) plus Lenvima (lenvatinib) met the primary endpoint of progression-free survival as first-line treatment of advanced renal cell carcinoma.
In a phase IIb study, Tavo (tavokinogene telseplasmid) in combination with Keytruda (pembrolizumab) led to a 30% overall response rate in the first 54 out of 100 planned patients who have rigorously defined anti-PD1 checkpoint resistant metastatic melanoma.
A new study reports that state-level lung cancer screening rates were not aligned with lung cancer burden.
A study by researchers at the University of Pennsylvania found that early and repeated exposures to diagnostic imaging, such as X-rays and CT scans, may increase the risk of testicular cancer.
A study published published in JNCCN—Journal of the National Comprehensive Cancer Network analyzes the cost-effectiveness of olaparib, a PARP inhibitor, in the treatment of metastatic pancreatic cancer.